| Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer BJ Stish, TM Pisansky, WS Harmsen, BJ Davis, KS Tzou, R Choo, ... Journal of Clinical Oncology 34 (32), 3864-3871, 2016 | 227 | 2016 |
| The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited MP Deek, K Van der Eecken, R Phillips, NR Parikh, PI Velho, TL Lotan, ... European urology 80 (5), 632-640, 2021 | 76 | 2021 |
| Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer RT Dess, Y Sun, WC Jackson, NK Jairath, AU Kishan, DG Wallington, ... JAMA oncology 6 (5), 735-743, 2020 | 68 | 2020 |
| Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer MP Deek, K Taparra, R Phillips, PI Velho, RW Gao, C Deville, DY Song, ... European urology oncology 4 (3), 447-455, 2021 | 59 | 2021 |
| Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging … RT Dess, K Suresh, MJ Zelefsky, SJ Freedland, BA Mahal, ... JAMA oncology 6 (12), 1912-1920, 2020 | 59 | 2020 |
| Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv BJ Stish, H Chen, Y Shu, A Panoskaltsis-Mortari, DA Vallera Clinical cancer research 13 (10), 3058-3067, 2007 | 53 | 2007 |
| Low dose rate prostate brachytherapy BJ Stish, BJ Davis, LA Mynderse, RH McLaren, CL Deufel, R Choo Translational andrology and urology 7 (3), 341, 2018 | 47 | 2018 |
| A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic … S Oh, BJ Stish, D Sachdev, H Chen, AZ Dudek, DA Vallera Clinical Cancer Research 15 (19), 6137-6147, 2009 | 43 | 2009 |
| Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model BJ Stish, S Oh, DA Vallera Journal of neuro-oncology 87, 51-61, 2008 | 39 | 2008 |
| Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity BJ Stish, S Oh, H Chen, AZ Dudek, RA Kratzke, DA Vallera British journal of cancer 101 (7), 1114-1123, 2009 | 33 | 2009 |
| Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? O Saifi, WG Breen, SC Lester, WG Rule, B Stish, A Rosenthal, J Munoz, ... Radiotherapy and Oncology 166, 171-179, 2022 | 32 | 2022 |
| Reirradiation for locoregional recurrent breast cancer S Fattahi, SK Ahmed, SS Park, IA Petersen, DA Shumway, BJ Stish, ... Advances in Radiation Oncology 6 (1), 100640, 2021 | 32 | 2021 |
| Stereotactic body radiation therapy for nonspine bone metastases: international practice patterns to guide treatment planning TK Nguyen, A Sahgal, R Dagan, W Eppinga, M Guckenberger, JH Kim, ... Practical radiation oncology 10 (6), e452-e460, 2020 | 32 | 2020 |
| A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer BJ Stish, H Chen, Y Shu, A Panoskaltsis-Mortari, DA Vallera Clinical cancer research 13 (21), 6486-6493, 2007 | 32 | 2007 |
| Patterns of recurrence after postprostatectomy fossa radiation therapy identified by C-11 choline positron emission tomography/computed tomography WP Parker, JD Evans, BJ Stish, SS Park, K Olivier, R Choo, MA Nathan, ... International Journal of Radiation Oncology* Biology* Physics 97 (3), 526-535, 2017 | 31 | 2017 |
| Patient‐reported functional and quality of life outcomes in a large cohort of long‐term survivors of Ewing sarcoma BJ Stish, SK Ahmed, PS Rose, CA Arndt, NN Laack Pediatric blood & cancer 62 (12), 2189-2196, 2015 | 29 | 2015 |
| Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model DA Vallera, BJ Stish, Y Shu, H Chen, A Saluja, DJ Buchsbaum, ... Gut 57 (5), 634-641, 2008 | 28 | 2008 |
| Permanent prostate brachytherapy monotherapy with I-125 for low-and intermediate-risk prostate cancer: Outcomes in 974 patients DM Routman, RK Funk, BJ Stish, LA Mynderse, TM Wilson, R McLaren, ... Brachytherapy 18 (1), 1-7, 2019 | 27 | 2019 |
| Long-term outcomes and patterns of failure after surgical resection of small-cell lung cancer BJ Stish, CL Hallemeier, KR Olivier, WS Harmsen, MS Allen, YI Garces Clinical lung cancer 16 (5), e67-e73, 2015 | 26 | 2015 |
| Prospective immunophenotyping of CD8+ T cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed SBRT JD Evans, LK Morris, H Zhang, S Cao, X Liu, KC Mara, BJ Stish, BJ Davis, ... International Journal of Radiation Oncology* Biology* Physics 103 (1), 229-240, 2019 | 25 | 2019 |
